Editorial: what can be done when infliximab stops working in ulcerative colitis?
<p style="text-align:justify;"> Currently the clinician managing secondary loss of anti‐tumour necrosis factor (TNF)‐α response in ulcerative colitis (UC) is faced with a difficult dilemma. Should he/she escalate the anti‐TNFα dose, switch to an alternative anti‐TNFα or biological (...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
Wiley
2015
|